Lung cancer remains the leading cause of cancer deaths in the United States. However, clinical advances in screening and treatment paradigms for lung cancer are improving outcomes for these patients. Lung cancer CME and CE is essential for clinicians to stay current with these evolving treatment options.
Important recent shifts in the treatment paradigm include the expanding role of immune checkpoint inhibitors for lung cancer as well as targeted therapies for an increasing list of therapeutically actionable driver mutations. In every case, continuing education regarding the optimal use of each of the available treatment options is critical, including patient selection, dosing and administration, and best practices for monitoring for adverse events.
Lung cancer CME is vital to developing and increasing the clinical skills, knowledge, and professional performance needed to effectively provide good care for patients with this disease.